Ubroseal Blue Dry Cow

120 x 1 pc

Intramammary Suspension

Active substance

Bismuth (Bismuth nitrate) : 2,6 g/sprøjte

ATC code

QG52X Various products for teats and udder

QG52 Products for teats and udder

QG Genito urinary system and sex hormones

Species

Cattle (dairy cows at drying off)

Indications

Prevention of new intramammary infections throughout the dry period.

In cows considered likely to be free of sub-clinical mastitis, the veterinary medicinal product can be used on its own in dry cow management and mastitis control.

Selection of cows for treatment with the veterinary medicinal product should be based on veterinary clinical judgement. Selection criteria may be based on the mastitis and cell count history of individual cows, or recognised tests for the detection of sub-clinical mastitis or bacteriological sampling.

Dose to be administered and administration route

For intramammary use only.

Infuse the contents of one syringe of the veterinary medicinal product into each udder quarter immediately after the last milking of the lactation (at drying off). Do not massage the teat or udder after infusion of the veterinary medicinal product.

Care must be taken not to introduce pathogens into the teat in order to reduce the risk of post-infusion mastitis.

It is essential that the teat is thoroughly cleaned and disinfected, with surgical spirit or alcohol-impregnated disinfecting towels. The teats should be wiped until the disinfecting towels are no longer visibly dirty. Teats should be allowed to dry prior to infusion. Infuse aseptically and take care to avoid contamination of the syringe nozzle. Following infusion it is advisable to use an appropriate teat dip or spray.

Under cold conditions the veterinary medicinal product may be warmed to room temperature in a warm environment to aid syringeability.

Adverse reactions

Cattle (dairy cow at dry-off):

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Acute mastitis ^¹

¹primarily due to poor infusion technique and lack of hygiene. Please refer to sections 4.5 and 4.9 regarding the importance of aseptic technique.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.